Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03818880

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression

Diurnal variations in the thickness of the choroid have been reported in the literature, and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Myopia, Progressive Eye Diseases Myopia Myopia, Degenerative Refractive Errors

Age range

6 year–10 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre for Ocular Research and Education

Waterloo, Ontario, N2L 3G1, Canada

About this study

Diurnal variations in the thickness of the choroid have been reported in the literature , and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression. SightGlass Vision, Inc is conducting a multi-site, randomized, controlled, interventional study to confirm the efficacy and safety of spectacle lenses designed to inhibit the progression of myopia by reducing image contrast in peripheral vision. CORE is participating as a clinical site in this three year study which aims to compare changes in ocular length and cycloplegic auto-refraction in children randomised to wear one of either two test or one control spectacle lens designs; the CPRO-1802-001 (Cypress_SG) study. The sponsor is interested in conducting choroidal thickness measurements only at CORE's site by inviting those participants who have already been found eligible for the CPRO-1802-001 study to participate in this parallel study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participating in the CPRO-1802-001 (Cypress_SG) study at CORE
  • Read and signed an Assent and their parent/guardian has signed an information consent letter

Exclusion criteria

  • Transient health condition which may affect the eye(s) (e.g. a common cold, active allergies, fatigue, etc;)

Treatment and study plan

Novel spectacle lens design

Device

Spectacle lens to control progression of myopia

Primary outcomes

  1. Choroidal thickness

    Time frame: 3 years

    Measurement of choroidal thickness by Triton optical coherence tomographer (OCT), including post-imaging analysis

Secondary outcomes

  1. Visual field

    Time frame: 3 years

    Assessment of visual field to determine if changes in peripheral visual function by Humphrey Visual Field Analyzer

Sponsors and collaborators

Lead sponsor

SightGlass Vision, Inc.

Industry

Collaborators

  • University of Waterloo

Registry information

Official study title

A Sub-Study to Assess the Choroidal Response to Novel Spectacle Lens to Control Myopia Progression (CHERRY)

Acronym: CHERRY

Important dates

Study start
2018
Primary completion
2022
Study completion
2026
First posted
Jan 28, 2019
Registry last updated
May 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.